Clinigen Group plc (OTCMKTS:CLIGF) is a global specialty pharmaceutical and services company headquartered in the United Kingdom. Since its founding in 1996, Clinigen has focused on improving patient access to medicines that are not commercially available or approved in a given territory. The company’s core mission is to bridge gaps in the global healthcare ecosystem by sourcing, manufacturing and distributing a portfolio of unlicensed and repurposed medicines for hospitals, specialist pharmacies and healthcare authorities.
Clinigen’s Commercial Medicines division provides named-patient and pre-approval access programs, enabling clinicians and patients to obtain critical therapies on a compassionate use or early-access basis. This arm of the business manages regulatory compliance, pharmacovigilance and supply chain logistics to ensure continuity of treatment for patients with unmet medical needs. Key therapy areas include oncology, rare diseases and critical care, where timely availability of investigational or out-of-market products can have a meaningful impact on patient outcomes.
In parallel, Clinigen’s Clinical Services division supports pharmaceutical and biotechnology companies throughout the drug development lifecycle. Services include clinical trial supply management, comparator sourcing and packaging, global distribution and ancillary trial support. By leveraging its regulatory know-how and global network, Clinigen helps sponsors navigate complex supply chains, reduce trial timelines and ensure product integrity from the manufacturing site to the patient’s bedside.
Today, Clinigen serves more than 80 markets across Europe, North America, Asia-Pacific and Latin America. Its operations encompass regional hubs in the UK, United States, Germany, Switzerland and Singapore. The company’s executive leadership team is led by Chief Executive Officer Paul Szomoru, whose extensive experience in specialty pharmaceuticals and clinical services has guided Clinigen’s strategic growth and international expansion. Under his stewardship, Clinigen continues to explore partnerships and acquisitions that align with its mission of enhancing global access to essential and innovative therapies.
AI Generated. May Contain Errors.
